Northwest Biotherapeutics to Present DCVax-L Survival Data at BNOS
Dr. Marnix Bosch, Chief Technical Officer of Northwest Biotherapeutics, will present new findings on survival outcomes for DCVax-L during the British Neuro-Oncology Society Annual Meeting. The presentation, scheduled for July 3 in the United Kingdom, utilizes propensity score matching to evaluate the immunotherapy’s impact on glioblastoma patients.
The analysis, titled "DCVax-L–Associated Survival Extension Assessed Through Propensity Score Matching Analyses," offers a granular look at the correlation between the personalized immune therapy and patient longevity. By applying propensity score matching, the company aims to refine the interpretation of its clinical data following the completion of its 331-patient Phase III trial for glioblastoma, an aggressive primary brain cancer.
Following the session, the company will publish the corresponding slide deck on its corporate website. This presentation arrives as Northwest Biotherapeutics awaits a regulatory decision on its Marketing Authorization Application in the UK. The firm continues to develop its dendritic cell-based platform, which includes both the lead DCVax-L program and the DCVax-Direct candidate for inoperable solid tumors.
Comments (0)
No comments yet. Be the first!